Maxipulmon

Butamirate citrate, the active ingredient in Maxipulmon, is an antitussive presented as an oral formulation for oral use. It is employed to relieve dry, non‑productive coughs in adults and children when appropriate, providing symptomatic relief without affecting mucus clearance.

GNH USA supplies Maxipulmon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company adheres to stringent manufacturing standards and provides reliable logistics support for global distribution.

Maxipulmon, containing butamirate citrate, is used to manage coughs by acting on the cough reflex pathway.

- Dry cough: reduces frequency and intensity of coughing episodes. - Non‑productive cough: provides symptomatic relief in coughs without sputum production. - Cough due to upper respiratory tract infections: alleviates irritation‑induced coughing.

Butamirate citrate may cause several adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset occurring shortly after ingestion. - Drowsiness: transient sleepiness, especially at higher doses. - Dizziness: brief sensation of light‑headedness. - Dry mouth: reduced salivation leading to throat discomfort. - Headache: mild to moderate head pain. - Gastrointestinal discomfort: mild abdominal cramping or discomfort.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or angioedema requiring medical attention. - Hepatic dysfunction: abnormal liver enzyme elevations in rare cases. - Severe hypersensitivity: anaphylactic-like reactions demanding urgent care.

When using Maxipulmon, consider the following safety measures.

- Pregnancy: consult a healthcare professional; safety has not been established. - Breastfeeding: avoid use unless advised by a physician. - Asthma or chronic respiratory disease: monitor for any worsening of symptoms. - Elderly patients: start with the lowest effective dose and observe for increased sedation. - Concomitant CNS depressants: assess for additive drowsiness. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Butamirate citrate can interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of enhanced central nervous system effects. - Strong CNS depressants (e.g., opioids, benzodiazepines): may cause excessive sedation or respiratory depression.

Moderate Interactions (Monitor Closely): - Alcohol: can increase drowsiness and impair coordination. - Antihistamines: may augment anticholinergic side effects. - Selective serotonin reuptake inhibitors (SSRIs): potential for increased serotonergic activity. - Other cough suppressants: combined use may lead to over‑suppression of the cough reflex.